GlassScriptPhysician profile
Dana C Sheedy
NPI 1114185675
$4,929.27
in general payments reported to CMS, 2019-2025
24 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $688 · 2022: $835 · 2023: $1,006 · 2024: $1,287 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.75 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $688.77 | 2021-2025 | |
| Janssen Biotech, INC. | $429.36 | 2021-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $425.08 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $374.54 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $354.29 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $289.83 | 2021-2024 | Dupixent |
| Genzyme Corporation | $288.22 | 2021-2024 | |
| Pfizer INC. | $212.14 | 2021-2025 | |
| Lilly USA, LLC | $208.45 | 2021-2025 | Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $132.47 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $123.54 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $122.82 | 2023-2025 | Sotyktu |
| Biofrontera INC. | $113.46 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $82.33 | 2022-2025 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $70.41 | 2021-2025 | Klisyri |
| Dermavant Sciences, INC. | $69.59 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $56.17 | 2023-2025 | Zoryve |
| Convatec INC. | $31.32 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $18.58 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $18.40 | 2023 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.13 | 2021 | |
| Vyne Pharmaceuticals INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Sheedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.